Table 1 Patient characteristics in seven cohorts with ICIs treatment
Study | n | Cancer types | NFE2L2 MU | Response to ICI (n, ORR) | Female | Male | ICIs treatment | Agea | TMBb | Mutation Countb |
|---|---|---|---|---|---|---|---|---|---|---|
DFCI | 176 | Bladder cancer, HNSCC, Kidney cancer, Lung cancer | 8 | 129(43) | 62 | 114 | CTLA-4/PD-1/PD-L1 | 59.7 (15.6) | NA | NA |
MSK | 155 | Melanoma, NSCLC | 9 | 99(56) | 71 | 84 | CTLA-4/PD-1/PD-L1 and /Chemotheragy | 62.2 (11.6) | 7.6 (3.5, 17.7) | 105 (226, 508) |
MSK1661 | 1661 | 11 cancer types | 49 | 0(0) | 627 | 1034 | CTLA-4/PD-1/PD-L1 and /Chemotheragy | 61.4 (13.7) | 5.9 (2.9, 11.2) | 4(6, 12) |
OAK | 324 | NSCLC | 20 | 257(46) | 121 | 203 | PD-1/PD-L1 | 63.6 (8.9) | 8 (4, 15) | NA |
Pender | 98 | 18 cancer types | 20 | 73(16) | 54 | 44 | CTLA-4/PD-1/PD-L1 and /Chemotheragy | 54.4 (13.1) | 7 (3, 11.3) | NA |
POPLAR | 105 | NSCLC | 12 | 81(16) | 33 | 72 | PD-1/PD-L1 | 61.3 (9.4) | 7 (3.8, 17) | NA |
PUCH | 92 | gastrointestinal cancer | 4 | 57(35) | 25 | 67 | CTLA-4/PD-1/PD-L1 | 56 (12.9) | 4.6 (2.5, 9.1) | NA |